CSL Limited (ASX:CSL)
Share Pricing & News Healthcare

AUD 301.89

3.23 (1.082%)
(As on 2022-12-03 10:10:41 AEDT)
Previous Close Open Close*
298.66 300.95 301.89
Market Cap Dividend Yield (Annualized)
AUD 145.576B 1.21%

Day Range
299.7L 303.5 H
52 WEEK HIGH LOW
240.1L 307.82 H

Chart Price & Information

Last Trade 301.89
Change% 1.0815
52 W H/L 307.820/240.100
EBITDA 3.465B
NPAT After Abnormal Items 3.273B
Equity 21.161B
ROE% 16.33%
Total Liabilities 19.986B
Total Revenue 15.35B
Cash and Cash Equivalents 15.149B

Stock Information

Share price 301.89
Market Cap 145.576B
Price/Gross Cash Flow 33.21
Dividend Yield Excluding Special 1.18%
Ending Shares 481.706M
52-Week Range 307.820-240.100
Gross DPS (AUD) 3.2566
Gross Dividend Yield (Annualized) 1.21%
Earnings Yield 2.400
Net Tangible Asset (NTA) 35.98
P/E ratio 41.667
Sector P/E --
EPS 696.76
EV/EBITDA 24.53
Net Profit Margin (%) 22.69%
Gross Cash Flows Per Share 8.31
Net Gearing -5.34%
Sales Per Share 32.43
Book Value Per Share 43.93

Similar Companies

Related Articles

About Company

CSL Limited (ASX:CSL) is a biotechnology firm that develops and delivers biotherapies and influenza vaccinations to people suffering from catastrophic diseases and chronic medical problems. CSL (ASX:CSL) offers a portfolio of life-saving medicines, including those for hemophilia. CSL Behring and Seqirus are among its parts. CSL Behring is involved in manufacturing, marketing and developing plasma therapies. It also conducts early-stage research on plasma and non-plasma therapies (excluding influenza), receives intellectual property license and royalty income.  Seqirus develops influenza-related medicines and manufactures and distributes non-plasma biotherapeutic treatments. CSL reported a net profit after tax of US$2.255 billion for the fiscal year ended 30 June 2022, a 6% decrease at constant currency (CC) and at the upper end of guidance, with sales increasing 3% at CC. CSL (ASX:CSL) stated in its annual report that it remained resilient to the external environment during the fiscal year 2021/22. The company's 2030 strategy and principles continue to guide its management and frontline employees alike. According to CSL, the company’s continuous and measured investment in the business has been a key enabler of success and the company will follow this strategy in future too. CSL said that its global capital investment program has progressed as planned, making excellent strides in its research and development (R&D) pipeline.     

Corporate Information


45 Poplar Road, PARKVILLE, VIC, AUSTRALIA, 3052

Phone:(03) 9389 1911

Website:http://www.csl.com.au/

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable
02/09/2021 $1.59 10% 30/06/2021 Final Dividend 30/09/2021
19/09/2011 $0.32 6% 30/06/2011 Final Dividend 14/10/2011
13/09/2010 $0.33 16% 30/06/2010 Final Dividend 08/10/2010
17/09/2007 $0.47 59% 30/06/2007 Final Dividend 12/10/2007

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2023-09-01 2023
Report (Prelim) 2023-08-16 2023
Report (Interim) 2023-02-15 2023